Saturday, March 14, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

World Health Report raises more questions than actually addressing answers

Researchers say that a World Health Organization (WHO) report on the pandemic’s origins offers an in-depth summary of available data, including unseen granular details. But much remains to be done to establish the provenance of the virus — knowledge that will help to prevent future pandemics.

The report was the result of a joint investigation between Chinese and international researchers that included a four-week trip earlier this year to Wuhan, China, where COVID-19 was first detected.

The details in the report were helpful, but didn’t include much new information, says David Robertson, a virologist at the University of Glasgow, UK. “The extensive data presented confirmed a lot of what was already known, particularly on the timing of events and early cases in Wuhan.”

Challenges remaining include finding the animal that probably carried the virus from bats to humans, and determining how that spillover into people occurred.

Source: World Health Organization & Nature

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!